文献速递艾滋病与性传播感染

宫内暴露于HIV和抗逆转录病毒药物的儿童神经发育障碍风险:法国全国队列研究

Risk of Neurodevelopmental Disorders in Children Exposed to HIV and Antiretrovirals In Utero: A National Cohort Study in France.
PubMed 文献 · Clin Infect Dis · 2025-01-01

基于法国国家健康数据系统2012至2022年数据,纳入9035名HIV母亲所生活产单胎儿童,均宫内暴露于抗逆转录病毒药物。匹配5项社会人口学标准和胎龄后,暴露儿童神经发育障碍发生率高于一般人群(HR 1.24,95%CI 1.04-1.47)。在替诺福韦-恩曲他滨暴露者中,利托那韦增强达芦那韦方案较其他蛋白酶抑制剂与更高的神经发育障碍及相关专科就诊合并发生率显著相关(log-rank P < .001)。

要点

  • 宫内暴露HIV和抗逆转录病毒药物的儿童神经发育障碍风险升高(HR 1.24,95%CI 1.04-1.47)。
  • 所有儿童同时暴露于HIV和抗逆转录病毒药物,无法区分母体感染与治疗各自的作用。
  • 替诺福韦-恩曲他滨暴露者中,利托那韦增强达芦那韦方案较其他蛋白酶抑制剂合并发生率更高(log-rank P < .001)。

核心结论

  • 宫内暴露于HIV和抗逆转录病毒药物的儿童发生多因素起源的神经发育障碍风险更高。

研究设计与样本

  • 基于法国国家健康数据系统2012至2022年数据的人群基础匹配队列研究。
  • 纳入所有活产单胎儿童,包括HIV母亲所生、全部产前暴露于抗逆转录病毒药物的儿童。
  • 共纳入6667363名活产单胎,其中9035名 born to mothers with HIV,均孕期暴露于抗逆转录病毒药物。
  • 随访长达11年(平均5.5年)。
  • 主要结局为依据国际疾病分类第十版诊断的神经发育障碍。

主要发现

  • 暴露儿童神经发育障碍总体发生率高于一般人群,即使匹配5项社会人口学标准和胎龄后仍如此(HR 1.24,95%CI 1.04-1.47)。
  • 所有儿童同时暴露于HIV和抗逆转录病毒药物,无法剖析母体感染与母体治疗各自的作用。
  • 在替诺福韦-恩曲他滨暴露者中,利托那韦增强达芦那韦方案较其他蛋白酶抑制剂与更高的神经发育障碍及相关专科就诊合并发生率显著相关(log-rank P < .001)。

局限性

  • 所有儿童均同时暴露于HIV和抗逆转录病毒药物,无法区分母体感染与母体治疗各自的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The health of children exposed but uninfected by human immunodeficiency virus (HIV) requires long-term assessment, in particular in terms of neurological and cognitive development. Numerous confounding factors have hampered such assessment, and published data are contradictory. METHODS: Using data from the French National Health Data System from 2012 to 2022, we conducted a population-based matched cohort study on all live-born single children, including those born to mothers with HIV, all prenatally exposed to antiretrovirals (ARVs). The primary outcome was the diagnosis of neurodevelopmental disorders according to the International Classification of Diseases, 10th Revision. The recourse to specialized consultations likely to indirectly reflect neurodevelopmental symptoms was also evaluated. Incidence was assessed using the Cox survival model. RESULTS: Of 6 667 363 live-born singletons, 9035 were born to mothers with HIV, all exposed to ARVs during pregnancy. Children were followed for up to 11 years (average, 5.5 years). Overall, the incidence of neurodevelopmental disorders among exposed children was higher than in the general population, even after matching for 5 sociodemographic criteria and gestational age (hazard ratio, 1.24 [95% confidence interval, 1.04-1.47]). It was not possible to dissect the respective role of maternal infection from that of maternal treatment, as all children were coexposed to HIV and ARVs. However, among those exposed to tenofovir-emtricitabine, the ritonavir-boosted darunavir-based combination was significantly associated with a higher combined incidence of neurodevelopmental disorders and related specialized consultations than other protease inhibitors (log-rank P < .001). CONCLUSIONS: Children exposed to HIV and ARVs in utero have a higher risk of developing neurodevelopmental disorders of multifactorial origin.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Collier M, Chouchana L, Frange P, et al. Risk of Neurodevelopmental Disorders in Children Exposed to HIV and Antiretrovirals In Utero: A National Cohort Study in France. Clin Infect Dis. 2025. PMID: 39905585. doi:10.1093/cid/ciae610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。